m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01597)
Name
ST-2987
Synonyms
ST-2987; CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220
    Click to Show/Hide
Status
Investigative
Structure
Formula
C17H15N3O5
InChI
1S/C17H15N3O5/c21-17(19-22)10-7-13-1-3-14(4-2-13)11-18-25-12-15-5-8-16(9-6-15)20(23)24/h1-11,22H,12H2,(H,19,21)/b10-7+,18-11+
InChIKey
IWWFFHDXUHSRDM-PFMZDYLOSA-N
PubChem CID
44138032
TTD Drug ID
D0T0SK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone deacetylase 2 (HDAC2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Histone deacetylase 2 (HDAC2) is a therapeutic target for ST-2987. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ST-2987 through regulating the expression of Histone deacetylase 2 (HDAC2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.